상세 보기
초록
In the 2023 series, we summarized the major clinical research advances in gynecologiconcology based on communications at the conference of Asian Society of GynecologicOncology Review Course. The review consisted of 1) Endometrial cancer: immunecheckpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export,CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2)Cer vical cancer: surger y in low-risk early-stage cer vical cancer, therapy for locally advancedstage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy,triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents andPARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnesseda landmark year, marked by several practice-changing outcomes with immune checkpointinhibitors and the reliable efficacy of PARP inhibitors and ADCs.
키워드
- 제목
- Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
- 저자
- Shim, S.-H.; Lee, J.-Y.; Lee, Y.-Y.; Park, J.-Y.; Lee, Y.J.; Kim, S.I.; Han, G.H.; Yang, E.J.; Noh, J.J.; Yim, G.W.; Son, J.-H.; Kim, N.K.; Kim, T.-H.; Kong, T.-W.; Choi, Y.J.; Cho, A.; Lim, H.; Jang, E.B.; Cho, H.W.; Suh, D.H.
- 발행일
- 2024-03
- 유형
- Review
- 권
- 35
- 호
- 2
- 페이지
- 1 ~ 19